Ectoenzymes controlling leukocyte traffic

European Journal of Immunology

Volumn 42, Issue 2, 2012, Pages 284-292

  Salmi, Marko ^a,b,c   Jalkanen, Sirpa ^a,b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Enzymes; Extravasation; Inflammation; Leukocyte migration; Substrates and products

Indexed keywords

5' NUCLEOTIDASE; ADAM10 ENDOPEPTIDASE; ADAM17 PROTEIN; ADAM8 PROTEIN; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 2; ADENOSINE TRIPHOSPHATE; ANTIBODY; AUTOTAXIN; BETA INTERFERON; CD157 ANTIGEN; CD203 ANTIGEN; CD38 ANTIGEN; CD39 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DIPEPTIDYL PEPTIDASE IV; ECTOENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEIN; MICROSOMAL AMINOPEPTIDASE; NUCLEOTIDASE; OXIDOREDUCTASE; PEPTIDASE; PROTEINASE; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1; VASCULAR ADHESION PROTEIN 1 ANTIBODY;

ARTICLE; B LYMPHOCYTE; BLOOD VESSEL PERMEABILITY; CATALYSIS; CELL MOTILITY; CELL SURFACE; CHEMOTAXIS; ENZYME ACTIVITY; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANIMALS; CATALYTIC DOMAIN; CELL MEMBRANE; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; LEUKOCYTES; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; NUCLEOTIDASES; OXIDOREDUCTASES; PEPTIDE HYDROLASES;

EID: 84856044295     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201142223     Document Type: Article

References (79)

1. Ley, K., Laudanna, C., Cybulsky, M. I. and Nourshargh, S., Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007. 7: 678-689.
2. Goding, J. W., Ecto-enzymes: physiology meets pathology. J. Leukoc. Biol. 2000. 67: 285-311.
3. Salmi, M. and Jalkanen, S., Cell-surface enzymes in control of leukocyte trafficking. Nat. Rev. Immunol. 2005. 5: 760-771.
4. Salmi, M. and Jalkanen, S., Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread. FEBS Lett. 2011. 585: 1543-1550.
5. Aspinall, A. I., Curbishley, S. M., Lalor, P. F., Weston, C. J., Liaskou, E., Adams, R. M., Holt, A. P. et al., CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. Hepatology 2010. 51: 2030-2039.
6. Bonder, C. S., Norman, M. U., Swain, M. G., Zbytnuik, L. D., Yamanouchi, J., Santamaria, P., Ajuebor, M. et al., Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: a role for α-4 integrin and vascular adhesion protein-1. Immunity 2005. 23: 153-163.
7. Stolen, C. M., Marttila-Ichihara, F., Koskinen, K., Yegutkin, G. G., Turja, R., Bono, P., Skurnik, M. et al., Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 2005. 22: 105-115.
8. Merinen, M., Irjala, H., Salmi, M., Jaakkola, I., Hänninen, A. and Jalkanen, S., Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am. J. Pathol. 2005. 166: 793-800.
9. Marttila-Ichihara, F., Smith, D. J., Stolen, C., Yegutkin, G. G., Elima, K., Mercier, N., Kiviranta, R. et al., Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum. 2006. 54: 2852-2862.
10. O'Rourke, A. M., Wang, E. Y., Miller, A., Podar, E. M., Scheyhing, K., Huang, L., Kessler, C. et al., Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J. Pharmacol. Exp. Ther. 2008. 324: 867-875.
11. Noda, K., Miyahara, S., Nakazawa, T., Almulki, L., Nakao, S., Hisatomi, T., She, H. et al., Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J. 2008. 22: 1094-1103.
12. Nakao, S., Noda, K., Zandi, S., Sun, D., Taher, M., Schering, A., Xie, F. et al., VAP-1-mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A-induced lymph- and angiogenesis. Am. J. Pathol. 2011. 178: 1913-1921.
13. Marttila-Ichihara, F., Castermans, K., Auvinen, K., Oude Egbrink, M. G., Jalkanen, S., Griffioen, A. W. and Salmi, M., Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice. J. Immunol. 2010. 184: 3164-3173.
14. Koskinen, K., Nevalainen, S., Karikoski, M., Hänninen, A., Jalkanen, S. and Salmi, M., VAP-1-deficient mice display defects in mucosal immunity and antimicrobial responses: implications for antiadhesive applications. J. Immunol. 2007. 179: 6160-6168.
15. Bour, S., Caspar-Bauguil, S., Iffiu-Soltesz, Z., Nibbelink, M., Cousin, B., Miiluniemi, M., Salmi, M. et al., Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 deficiency reduces leukocyte infiltration into adipose tissue and favors fat deposition. Am. J. Pathol. 2009. 174: 1075-1083.
16. Marttila-Ichihara, F., Auvinen, K., Elima, K., Jalkanen, S. and Salmi, M., Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors. Cancer Res. 2009. 69: 7875-7883.
17. Kivi, E., Elima, K., Aalto, K., Nymalm, Y., Auvinen, K., Koivunen, E., Otto, D. M. et al., Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. Blood 2009. 114: 5385-5392.
18. Aalto, K., Autio, A., Kiss, E. A., Elima, K., Nymalm, Y., Veres, T. Z., Marttila-Ichihara, F. et al., Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer. Blood 2011. 118: 3725-3733.
19. Lalor, P. F., Sun, P. J., Weston, C. J., Martin-Santos, A., Wakelam, M. J. and Adams, D. H., Activation of vascular adhesion protein-1 on liver endothelium results in an NF-κB-dependent increase in lymphocyte adhesion. Hepatology 2007. 45: 465-474.
20. Sole, M., Hernandez-Guillamon, M., Boada, M. and Unzeta, M., p53 phosphorylation is involved in vascular cell death induced by the catalytic activity of membrane-bound SSAO/VAP-1. Biochim. Biophys. Acta 2008. 1783: 1085-1094.
21. Jalkanen, S., Karikoski, M., Mercier, N., Koskinen, K., Henttinen, T., Elima, K., Salmivirta, K. et al., The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. Blood 2007. 110: 1864-1870.
22. Liaskou, E., Karikoski, M., Reynolds, G. M., Lalor, P. F., Weston, C. J., Pullen, N., Salmi, M. et al., Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 2011. 53: 661-672.
23. Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T. et al., Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 2008. 88: 841-886.
24. + is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J. Biol. Chem. 2006. 281: 31419-31429.
25. Klein, C., Grahnert, A., Abdelrahman, A., Muller, C. E. and Hauschildt, S., Extracellular NAD(+) induces a rise in [Ca(2+)](i) in activated human monocytes via engagement of P2Y(1) and P2Y(11) receptors. Cell Calcium 2009. 46: 263-272.
26. Deaglio, S. and Robson, S. C., Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv. Pharmacol. 2011. 61: 301-332.
27. Frasca, L., Fedele, G., Deaglio, S., Capuano, C., Palazzo, R., Vaisitti, T., Malavasi, F. et al., CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells. Blood 2006. 107: 2392-2399.
28. 2+ level and motility of lymphokine-activated killer cells. J. Biol. Chem. 2005. 280: 2888-2895.
29. Partida-Sanchez, S., Gasser, A., Fliegert, R., Siebrands, C. C., Dammermann, W., Shi, G., Mousseau, B. J. et al., Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by ADP-ribose, the major product generated by the CD38 enzyme reaction. J. Immunol. 2007. 179: 7827-7839.
30. 2+ signaling in interleukin-8-treated lymphokine-activated killer cells. J. Biol. Chem. 2010. 285: 21877-21887.
31. Shi, G., Partida-Sanchez, S., Misra, R. S., Tighe, M., Borchers, M. T., Lee, J. J., Simon, M. I. et al., Identification of an alternative G}alpha{q-dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes. J. Exp. Med. 2007. 204: 2705-2718.
32. Choe, C. U., Lardong, K., Gelderblom, M., Ludewig, P., Leypoldt, F., Koch-Nolte, F., Gerloff, C. et al., CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia. PLoS One 2011. 6: e19046.
33. Deaglio, S., Vaisitti, T., Aydin, S., Bergui, L., D'Arena, G., Bonello, L., Omede, P. et al., CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007. 110: 4012-4021.
34. Vaisitti, T., Aydin, S., Rossi, D., Cottino, F., Bergui, L., D'Arena, G., Bonello, L. et al., CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010. 24: 958-969.
35. Lo Buono, N., Parrotta, R., Morone, S., Bovino, P., Nacci, G., Ortolan, E., Horenstein, A. L. et al., The CD157-integrin partnership controls transendothelial migration and adhesion of human monocytes. J. Biol. Chem. 2011. 286: 18681-18691.
36. Haag, F., Adriouch, S., Brass, A., Jung, C., Moller, S., Scheuplein, F., Bannas, P. et al., Extracellular NAD and ATP: Partners in immune cell modulation. Purinergic Signal 2007. 3: 71-81.
37. + and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. J. Immunol. 2009. 182: 2898-2908.
38. + regulatory T cell compartment through the ART2-P2X7 pathway. J. Exp. Med. 2010. 207: 2561-2568.
39. Junger, W. G., Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 2011. 11: 201-212.
40. Hyman, M. C., Petrovic-Djergovic, D., Visovatti, S. H., Liao, H., Yanamadala, S., Bouis, D., Su, E. J. et al., Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J. Clin. Invest. 2009. 119: 1136-1149.
41. Reutershan, J., Vollmer, I., Stark, S., Wagner, R., Ngamsri, K. C. and Eltzschig, H. K., Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 2009. 23: 473-482.
42. Yegutkin, G. G., Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 2008. 1783: 673-694.
43. Ålgars, A., Karikoski, M., Yegutkin, G. G., Stoitzner, P., Niemelä, J., Salmi, M. and Jalkanen, S., Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 2011. 117: 4387-4393.
44. Eckle, T., Krahn, T., Grenz, A., Kohler, D., Mittelbronn, M., Ledent, C., Jacobson, M. A. et al., Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007. 115: 1581-1590.
45. Zernecke, A., Bidzhekov, K., Ozuyaman, B., Fraemohs, L., Liehn, E. A., Luscher-Firzlaff, J. M., Luscher, B. et al., CD73/ecto-5′-nucleotidase protects against vascular inflammation and neointima formation. Circulation 2006. 113: 2120-2127.
46. Kiss, J., Yegutkin, G. G., Koskinen, K., Savunen, T., Jalkanen, S. and Salmi, M., IFN-β protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol. 2007. 37: 3334-3338.
47. Yegutkin, G. G., Marttila-Ichihara, F., Karikoski, M., Niemelä, J., Laurila, J., Elima, K., Jalkanen, S. et al., Altered purinergic signalling in CD73 deficient mice inhibits tumor progression by regulating immunosuppressive leukocytes. Eur. J. Immunol. 2011. 41: 1231-1241.
48. Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W., Darcy, P. K. and Smyth, M. J., CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011. 71: 2892-2900.
49. Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J. and Zhang, B., CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 2011. 121: 2371-2382.
50. Moolenaar, W. H. and Perrakis, A., Insights into autotaxin: How to produce and present a lipid mediator. Nat. Rev. Mol. Cell Biol. 2011. 12: 674-679.
51. Kanda, H., Newton, R., Klein, R., Morita, Y., Gunn, M. D. and Rosen, S. D., Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat. Immunol. 2008. 9: 415-423.
52. Nakasaki, T., Tanaka, T., Okudaira, S., Hirosawa, M., Umemoto, E., Otani, K., Jin, S. et al., Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions. Am. J. Pathol. 2008. 173: 1566-1576.
53. Zhou, Z., Subramanian, P., Sevilmis, G., Globke, B., Soehnlein, O., Karshovska, E., Megens, R. et al., Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 2011. 13: 592-600.
54. Tania, M., Khan, M. A., Zhang, H., Li, J. and Song, Y., Autotaxin: a protein with two faces. Biochem. Biophys. Res. Commun. 2010. 401: 493-497.
55. Busso, N., Wagtmann, N., Herling, C., Chobaz-Peclat, V., Bischof-Delaloye, A., So, A. and Grouzmann, E., Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am. J. Pathol. 2005. 166: 433-442.
56. Preller, V., Gerber, A., Wrenger, S., Togni, M., Marguet, D., Tadje, J., Lendeckel, U. et al., TGF-β1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J. Immunol. 2007. 178: 4632-4640.
57. Yan, S., Gessner, R., Dietel, C., Schmiedek, U. and Fan, H., Enhanced ovalbumin-induced airway inflammation in CD26(-/-) mice. Eur. J. Immunol. 2011. Doi:10.1002/eji.201041038 [Epub ahead of print].
58. Proost, P., Mortier, A., Loos, T., Vandercappellen, J., Gouwy, M., Ronsse, I., Schutyser, E. et al., Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007. 110: 37-44.
59. Paulissen, G., Rocks, N., Gueders, M. M., Bedoret, D., Crahay, C., Quesada-Calvo, F., Hacha, J. et al., ADAM-8, a metalloproteinase, drives acute allergen-induced airway inflammation. Eur. J. Immunol. 2011. 41: 380-391.
60. Tang, J., Zarbock, A., Gomez, I., Wilson, C. L., Lefort, C. T., Stadtmann, A., Bell, B. et al., Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites. Blood 2011. 118: 786-794.
61. Koenen, R. R., Pruessmeyer, J., Soehnlein, O., Fraemohs, L., Zernecke, A., Schwarz, N., Reiss, K. et al., Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood 2009. 113: 4799-4809.
62. Schulz, B., Pruessmeyer, J., Maretzky, T., Ludwig, A., Blobel, C. P., Saftig, P. and Reiss, K., ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ. Res. 2008. 102: 1192-1201.
63. Arndt, P. G., Strahan, B., Wang, Y., Long, C., Horiuchi, K. and Walcheck, B., Leukocyte ADAM17 regulates acute pulmonary inflammation. PLoS One 2011. 6: e19938.
64. Van Lint, P. and Libert, C., Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 2007. 82: 1375-1381.
65. Niemelä, J., Ifergan, I., Yegutkin, G. G., Jalkanen, S., Prat, A. and Airas, L., IFN-β regulates CD73 and adenosine expression at the blood-brain barrier. Eur. J. Immunol. 2008. 38: 2718-2726.
66. Regateiro, F. S., Howie, D., Nolan, K. F., Agorogiannis, E. I., Greaves, D. R., Cobbold, S. P. and Waldmann, H., Generation of anti-inflammatory adenosine byleukocytes is regulated by TGF-β. Eur. J. Immunol. 2011. 41: 2955-2965.
67. Baetta, R. and Corsini, A., Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011. 71: 1441-1467.
68. Campbell, R. K., Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin. Ther. 2011. 33: 511-527.
69. Kirkwood, K. S., Bunnett, N. W., Maa, J., Castagliolo, I., Liu, B., Gerard, N., Zacks, J. et al., Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A. Am. J. Physiol. Gastrointest. Liver Physiol. 2001. 281: G544-G551.
70. Christopherson, K. W., II, Hangoc, G., Mantel, C. R. and Broxmeyer, H. E., Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004. 305: 1000-1003.
71. Partida-Sanchez, S., Cockayne, D. A., Monard, S., Jacobson, E. L., Oppenheimer, N., Garvy, B., Kusser, K. et al., Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med. 2001. 7: 1209-1216.
72. Partida-Sanchez, S., Goodrich, S., Kusser, K., Oppenheimer, N., Randall, T. D. and Lund, F. E., Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 2004. 20: 279-291.
73. Chen, Y. G., Chen, J., Osborne, M. A., Chapman, H. D., Besra, G. S., Porcelli, S. A., Leiter, E. H. et al., CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice. J. Immunol. 2006. 177: 2939-2947.
74. Lund, F. E., Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity. Mol. Med. 2006. 12: 328-333.
75. Goepfert, C., Sundberg, C., Sevigny, J., Enjyoji, K., Hoshi, T., Csizmadia, E. and Robson, S., Disordered cellular migration and angiogenesis in CD39-null mice. Circulation 2001. 104: 3109-3115.
76. Mizumoto, N., Kumamoto, T., Robson, S. C., Sevigny, J., Matsue, H., Enjyoji, K. and Takashima, A., CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat. Med. 2002. 8: 358-365.
77. Eltzschig, H. K., Thompson, L. F., Karhausen, J., Cotta, R. J., Ibla, J. C., Robson, S. C. and Colgan, S. P., Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004. 104: 3986-3992.
78. Koszalka, P., Ozuyaman, B., Huo, Y., Zernecke, A., Flogel, U., Braun, N., Buchheiser, A. et al., Targeted disruption of CD73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 2004. 95: 814-821.
79. Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C., Russell, W. E. et al., An essential role for ectodomain shedding in mammalian development. Science 1998. 282: 1281-1284.